Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 9/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22510538 | 0.88 | SLC5A2 (0.44) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL147738 | 0.85 | SLC5A2 (0.42) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL146751 | 0.84 | SLC5A2 (0.41) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL12714458 | 0.83 | SLC5A2 (0.56) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL23221106 | 0.82 | SLC5A2 (0.46) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL16309204 | 0.82 | SLC5A2 (0.42) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL147317 | 0.80 | SLC5A2 (0.46) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL148036 | 0.80 | CYP11B1 (0.42) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL28831161 | 0.79 | SLC5A2 (0.51) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL29845909 | 0.79 | SLC5A2 (0.51) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885ABCB11 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.